ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.96129
-0.07%
Brent Oil
83.805
0.21%
Bitcoin
59,527.86
0.69%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) Noticias

VSTM Verastem Inc

10.36
0.38 (3.81%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Verastem Inc VSTM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.38 3.81% 10.36 17:12:15
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
10.01 9.81 10.45 10.36 9.98
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202415:05BWVerastem Oncology Announces Appointment of John Hayslip,..
04/4/202406:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
18/3/202406:00BWGlobal Patient Survey Results Reveal Significant Negative..
14/3/202415:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
11/3/202416:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/3/202406:30BWVerastem Oncology Announces Multiple Oral Presentations at..
05/3/202416:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
05/3/202415:30BWVerastem Oncology Announces Preclinical Presentations for..
08/2/202415:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
02/2/202408:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202415:01EDGAR2Form 8-K - Current report
29/1/202406:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
19/1/202406:54EDGAR2Form 8-K - Current report
18/1/202415:00BWVerastem Oncology Granted Fast Track Designation for..
11/1/202406:00BWVerastem Oncology to Participate in the B. Riley Securities..
09/1/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:02EDGAR2Form 8-K - Current report
05/1/202406:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/12/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:01EDGAR2Form DEF 14A - Other definitive proxy statements
18/12/202306:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
13/12/202306:00BWVerastem Oncology Announces Initiation of a Confirmatory..
08/12/202315:10EDGAR2Form PRE 14A - Other preliminary proxy statements
20/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202306:00BWNew Healthcare Professional Component of Let’s Talk About..
08/11/202316:01EDGAR2Form S-3 - Registration statement under Securities Act of..
08/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
07/11/202306:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
06/11/202306:00BWVerastem Oncology Announces Efficacy and Safety Data of..
27/10/202315:41EDGAR2Form 8-K - Current report
26/10/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202315:05BWVerastem Oncology Strengthens Executive Leadership Team with..
18/10/202315:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
14/10/202311:30BWVerastem Oncology Announces Initial Results of RAMP 203..
10/10/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202306:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/9/202313:27EDGAR2Form 8-K - Current report
28/9/202313:15BWVerastem Presents Avutometinib and Defactinib Combination..
25/9/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202315:08EDGAR2Form 8-K - Current report
05/9/202306:00BWVerastem Oncology to Participate in Upcoming Investor..
28/8/202306:00BWVerastem Oncology Enters Discovery and Development..
08/8/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:05BWVerastem Oncology Reports Second Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
VSTM
Verastem
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados